Navigation Links
Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals plc
Date:9/19/2011

accounting rules and methodologies; and the possibility that if the combined company does not achieve the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of the combined company's shares could decline, as well as other risks related to Jazz Pharmaceuticals' business, including Jazz Pharmaceuticals' dependence on sales of Xyrem and its ability to increase sales of its Xyrem and Luvox CR products; competition, including potential generic competition; Jazz Pharmaceuticals' dependence on single source suppliers and manufacturers; the ability of Jazz Pharmaceuticals to protect its intellectual property and defend its patents; regulatory obligations and oversight; Jazz Pharmaceuticals' cash flow; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' SEC filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011.  Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Additional Information and Where to Find It

In connection with the proposed transaction, Jazz Pharmaceuticals and Azur Pharma will be filing documents with the SEC, including the filing by Jazz Pharmaceuticals of a preliminary and definitive proxy statement/prospectus relating to the proposed transaction and the filing by Azur Pharma of a registration statement on Form S-4 that will include the proxy statement/prospectus relating to the proposed transaction.  After the registration statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to Jazz Pharmaceuticals' stockholders in connection with the proposed transaction.  INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
2. Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
3. Jazz Pharmaceuticals Announces Presentation at the UBS Global Life Sciences Conference in New York on September 20
4. Avanir Pharmaceuticals to Participate in Two Investor Conferences
5. Qualitest Pharmaceuticals Issues a Nationwide Voluntary Recall of Oral Contraceptives
6. Oramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011
7. Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
8. AcelRx Pharmaceuticals to Present at Two Healthcare Investor Conferences in the Second Half of September
9. Vanda Pharmaceuticals to Participate in UBS Global Life Sciences Conference
10. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
11. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Corporation (Nasdaq: IRIX ) today reported financial results ... , Revenues were $11.8 million in the fourth ... 11% from $10.6 million in the 2013 fourth quarter. Revenues ... from $38.3 million in 2013. , Gross margin for ... the fourth quarter of the prior year. , Operating ...
(Date:3/5/2015)... SEATTLE und TÜBINGEN, Deutschland, 5. ... Melinda Gates Stiftung und das deutsche biopharmazeutische ... Stiftung 46 Millionen Euro (52 Millionen US-Dollar) ... im Bereich der medizinisch angewandten Messenger-RNA (mRNA). ... neue Ansätze zur Behandlung von Krankheiten und ...
(Date:3/5/2015)... TÜBINGEN, Germany , March 5, ... Foundation and CureVac today announced that the foundation ... (€46 million) in CureVac, a leading clinical-stage biopharmaceutical ... of the agreement, the foundation will also provide ... vaccines based on CureVac,s proprietary messenger RNA (mRNA) ...
Breaking Medicine Technology:IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4
... 16 According to the Centers for Disease Control and ... influenza activity - and nearly all influenza cases reported to ... flu. However, with the release of a 2009 H1N1 ... help keep their families safe from illness. , Like seasonal ...
... Oct. 15 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ... M. Culley, will present at the BIOCOM Investor Conference on ... the Hyatt Regency in La Jolla, California. , Interested parties ... the ADVENTRX Pharmaceuticals Web site at www.adventrx.com ...
Cached Medicine Technology:With 2009 H1N1 Cases on the Rise, New CDC-Recommended Vaccine Helps Protect Families Against Illness 2With 2009 H1N1 Cases on the Rise, New CDC-Recommended Vaccine Helps Protect Families Against Illness 3
(Date:3/5/2015)... AxoGen, Inc. (NASDAQ: AXGN) , ... nerve repair market, reported record revenue of $4.79 million ... to $2.98 million in the year-ago fourth quarter demonstrating ... , “Our strong fourth quarter revenue growth reflects the ... which is driving increased surgeon adoption of our unique ...
(Date:3/5/2015)... NY (PRWEB) March 05, 2015 ... forward in a Pennsylvania mass tort litigation currently ... where a jury has begun hearing testimony in ... the atypical antipsychotic medication can cause gynecomastia, or ... case in question was filed on behalf of ...
(Date:3/5/2015)... 05, 2015 Testosterone lawsuits ( http://www.testosteronelawsuithub.com/ ... heart attacks, strokes and other serious cardiovascular events due ... to move forward in the federal multidistrict litigation now ... According to a Case Management Order issued on March ... use of master pleadings in the proceeding. Among other ...
(Date:3/5/2015)... Central Nebraska Imaging (CNI) is pleased to ... new logo and optimized website. , CNI’s ... to expert diagnostic imaging, centered on patient care. The ... be a resource for Nebraska patients and a tool ... and referral functionality, video content and resources to understand ...
(Date:3/5/2015)... RI (PRWEB) March 05, 2015 Rhode Island ... third year in a row to support the Providence College ... The donation covered the purchase of the ‘Think Pink’ uniforms, ... against Big East Conference opponent DePaul University at Alumni Hall/Mullaney ... to continue our support of the PC women’s basketball’s ‘Pink ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2
... Drug Information Association (DIA), in collaboration with FDA, the Medical ... Radiopharmaceuticals (CORAR), PhRMA, and the American Medical Informatics Association (AMIA), ... Uses of Medical Imaging in the Development of New Biopharmaceutical ... ...
... is a break-through Nitinol wire product which features an exclusive ... acid solutions which cause embrittlement. The resulting NitiBrite™ ... other known methods. , ... West ...
... Komen for the Cure(R), the,leader of the global ... G. Komen for the Cure Advocacy Alliance, have ... self awareness and the need for,increased access to ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ), Komen for the ...
... Companies Will Discuss Recent FDA Advisory Regarding Byetta, ... LLY ) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... 2008 at 5:00 p.m. EDT to discuss the,recent FDA ... Lilly will be Donald Therasse, M.D., vice president of ...
... fail to alert docs to effectiveness of alternative therapies ... slowed the use of antipsychotic drugs in seniors with ... the elderly increased, a finding which suggests that warnings ... say. , Between late 2002 and June 2005, ...
... HCA marked its 40th,anniversary during a special program for ... featured HCA Co-Founder and Chairman Emeritus, Dr. Thomas,Frist, Jr. ... who spoke about,HCA,s founding, mission and tradition of caring ... of Caring" program was a,prelude to HCA,s annual Caring ...
Cached Medicine News:Health News:Shaping Best Practices For Standardized Medical Imaging In Clinical Trials 2Health News:Shaping Best Practices For Standardized Medical Imaging In Clinical Trials 3Health News:NitiBrite™ - Break-through in Nitinol Wire Product for Medical Devices 2Health News:Komen Travels to Democratic Convention in Denver to Raise Awareness of Breast Cancer Issues 2Health News:Lilly and Amylin Set Date and Time for Conference Call 2Health News:Antipsychotic Drug Use Up in Elderly Despite Warnings 2Health News:HCA Celebrates 40th Anniversary 2
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical...
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical...
... The LT-Cage device restores ... with significantly less reaming ... Medtronic Sofamor Danek's Tapered ... to easily and reproducibly ...
Medicine Products: